PDF(Pubmed)
Abstract：
UNASSIGNED: Approximately 20% of patients with type I endometrial cancer (EC) of the uterus experience recurrence and metastasis. However, existing data do not provide sufficient evidence for the utility of protein levels as prognostic biomarkers in type I EC. This study aims to determine whether epiplakin1 (EPPK1) and progesterone receptor (PR) play a role in the recurrence and metastasis of type I EC.
UNASSIGNED: Following the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) for assessing the quality of biomarker research results, a retrospective analysis was conducted on clinical information and tissue samples of type I EC patients. Protein expression data and clinical data for type I EC were downloaded from The Cancer Proteome Atlas (TCPA) database. We utilized the Kaplan-Meier (K-M) method and Cox proportional hazards regression analyses to evaluate whether epiplakin1 (EPPK1), progesterone receptor (PR) and certain clinical parameters can serve as independent prognostic factors. The Immune Cell Abundance Identifier (ImmuCellAI) and Cancer Immunome Atlas (TCIA) were employed to predict responses to immunotherapy. Immunohistochemistry was carried out to assess the expression of EPPK1 in type I EC.
UNASSIGNED: Type I EC patients with high EPPK1 and low PR expression had higher International Federation of Gynecology and Obstetrics (FIGO) stage, recurrence, and metastasis rates. Furthermore, EPPK1 was identified as an independent prognostic factor, and low expression of EPPK1 was predominantly observed in the POLE ultramutated (POLEmut) group, indicating a favorable prognosis. Additionally, the high EPPK1 expression group had a lower Immune Prognostic Score (IPS), suggesting that the high-expression group may not benefit from immune checkpoint inhibitors.
UNASSIGNED: High expression of EPPK1 is an independent prognostic factor in type I EC patients with low PR expression. It can identify a subgroup of patients at high risk of recurrence. A more aggressive treatment approach is recommended for these patients.
UNASSIGNED: Following the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) for assessing the quality of biomarker research results, a retrospective analysis was conducted on clinical information and tissue samples of type I EC patients. Protein expression data and clinical data for type I EC were downloaded from The Cancer Proteome Atlas (TCPA) database. We utilized the Kaplan-Meier (K-M) method and Cox proportional hazards regression analyses to evaluate whether epiplakin1 (EPPK1), progesterone receptor (PR) and certain clinical parameters can serve as independent prognostic factors. The Immune Cell Abundance Identifier (ImmuCellAI) and Cancer Immunome Atlas (TCIA) were employed to predict responses to immunotherapy. Immunohistochemistry was carried out to assess the expression of EPPK1 in type I EC.
UNASSIGNED: Type I EC patients with high EPPK1 and low PR expression had higher International Federation of Gynecology and Obstetrics (FIGO) stage, recurrence, and metastasis rates. Furthermore, EPPK1 was identified as an independent prognostic factor, and low expression of EPPK1 was predominantly observed in the POLE ultramutated (POLEmut) group, indicating a favorable prognosis. Additionally, the high EPPK1 expression group had a lower Immune Prognostic Score (IPS), suggesting that the high-expression group may not benefit from immune checkpoint inhibitors.
UNASSIGNED: High expression of EPPK1 is an independent prognostic factor in type I EC patients with low PR expression. It can identify a subgroup of patients at high risk of recurrence. A more aggressive treatment approach is recommended for these patients.
摘要：
■大约20％的子宫I型子宫内膜癌（EC）患者经历复发和转移。然而,现有数据没有提供足够的证据证明蛋白质水平作为I型EC的预后生物标志物。这项研究旨在确定epipplakin1（EPPK1）和孕激素受体（PR）是否在I型EC的复发和转移中起作用。
遵循肿瘤标志物预后研究报告建议（REMARK），以评估生物标志物研究结果的质量，我们对I型EC患者的临床资料和组织样本进行了回顾性分析.从癌症蛋白质组图谱(TCPA)数据库下载I型EC的蛋白质表达数据和临床数据。我们利用Kaplan-Meier(K-M)方法和Cox比例风险回归分析来评估epilakin1(EPPK1)孕激素受体（PR）和某些临床参数可以作为独立的预后因素。免疫细胞丰度标识符(ImmuCellAI)和癌症免疫图谱(TCIA)用于预测对免疫疗法的反应。进行免疫组织化学以评估I型EC中EPPK1的表达。
■高EPPK1和低PR表达的I型EC患者具有较高的国际妇产科联合会（FIGO）分期，复发,和转移率。此外，EPPK1被确定为独立的预后因素，在POLE超突变（POLEmut）组中主要观察到EPPK1的低表达，表明预后良好。此外,高EPPK1表达组的免疫预后评分（IPS）较低，提示高表达组可能无法从免疫检查点抑制剂中获益.
■EPPK1的高表达是PR低表达的I型EC患者的独立预后因素。它可以识别复发风险高的患者亚组。建议对这些患者采取更积极的治疗方法。
遵循肿瘤标志物预后研究报告建议（REMARK），以评估生物标志物研究结果的质量，我们对I型EC患者的临床资料和组织样本进行了回顾性分析.从癌症蛋白质组图谱(TCPA)数据库下载I型EC的蛋白质表达数据和临床数据。我们利用Kaplan-Meier(K-M)方法和Cox比例风险回归分析来评估epilakin1(EPPK1)孕激素受体（PR）和某些临床参数可以作为独立的预后因素。免疫细胞丰度标识符(ImmuCellAI)和癌症免疫图谱(TCIA)用于预测对免疫疗法的反应。进行免疫组织化学以评估I型EC中EPPK1的表达。
■高EPPK1和低PR表达的I型EC患者具有较高的国际妇产科联合会（FIGO）分期，复发,和转移率。此外，EPPK1被确定为独立的预后因素，在POLE超突变（POLEmut）组中主要观察到EPPK1的低表达，表明预后良好。此外,高EPPK1表达组的免疫预后评分（IPS）较低，提示高表达组可能无法从免疫检查点抑制剂中获益.
■EPPK1的高表达是PR低表达的I型EC患者的独立预后因素。它可以识别复发风险高的患者亚组。建议对这些患者采取更积极的治疗方法。
